Spirax Group plc (SPX)
London Exchange · UK · prices in GBX · close of 19 Oct 2026
Key indicators
| Last close | GBX 7,415.00 |
|---|---|
| 52-week range | 5,909.06 – 7,864.69 |
| Return, 1 month / 3 months | +8.1% / +8.6% |
| Return, 1 year / 3 years | +11.0% / −3.7% |
| Trend | Uptrend |
| RSI (14) | 62 |
| Volatility (1 year) | 26.8% |
| Worst drawdown (1 year) | -19.5% |
| Average daily value traded | 1,478.52M GBX |
| Dividend yield | 0.0% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Spirax Group is a British industrial engineering company based in Cheltenham. It designs and supplies equipment for managing steam and thermal energy in industrial processes, along with peristaltic pumps and fluid handling systems through its Watson-Marlow business. Its customers are manufacturers and process plants across many industries that need reliable ways to control heat, fluids and related services. The company supports these customers with engineering expertise, installation and maintenance of its products.
The shares are listed on the London Exchange in UK under the code SPX, and the price on this page is in pence sterling (GBX). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Spirax Group plc (SPX) trades on the London Exchange in UK. It last closed at GBX 7,415.00 on 19 October 2026.
Its price-based Market X-Ray is 66 out of 100 (a fair price profile), ranking 842 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 11.0% and over the last three months it rose 8.6%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 65 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 5.6% | ||
| From 52-week high | -4.7% | ||
| Momentum | 58 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 8.6% | ||
| 6-month return | 1.3% | ||
| 12-month return, skipping the last month | 2.7% | ||
| Stability (higher is calmer) | 72 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 26.8% | ||
| Worst drawdown, 1 year (smaller is calmer) | -19.5% | ||
| Liquidity | 98 · Strong | Trades actively. | |
| Average daily value traded | 1,478.52M GBX | ||
| Zero-volume days | 0.0% | ||
| Income | 25 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.0% | ||
| Years with dividends | 5 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Liquidity: Trades actively.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | +2.6% |
|---|---|
| 1 month | +8.1% |
| 3 months | +8.6% |
| 6 months | +1.3% |
| 1 year | +11.0% |
| 3 years | −3.7% |
| 5 years | −46.2% |
Signals
| 50-day / 200-day average | 7,058.26 / 7,020.62 |
|---|---|
| Golden / death cross (60 days) | Golden, 19 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 168.33 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 15 Oct 2026 | GBP 0.5040 |
| 23 Apr 2026 | GBP 1.2110 |
| 16 Oct 2025 | GBP 0.4890 |
| 24 Apr 2025 | GBP 1.1750 |
| 17 Oct 2024 | GBP 0.4750 |
| 25 Apr 2024 | GBP 1.1400 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.